Clinical Trial Update: CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) [Phase 4]

View source ↗

Summary

Phase 4 trial assessing metabolic and safety outcomes of Hylenex Recombinant administered preadministered at CSII infusion sites in adults with Type 1 Diabetes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• HYLENEX RECOMBINANT (HYALURONIDASE)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Type 1 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2014-10-29